Bristol Myers Squibb’s Abecma: First CAR T Cell Therapy Approved in EU for Multiple Myeloma

Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for treating adult patients with relapsed and refractory multiple myeloma who have undergone at least two prior therapies, including specific…

Read MoreBristol Myers Squibb’s Abecma: First CAR T Cell Therapy Approved in EU for Multiple Myeloma

Takeda announces FDA approval for ICLUSIG® in new Ph+ ALL.

Takeda (TSE:4502/NYSE:TAK) announced today that the FDA has approved ICLUSIG® (ponatinib) through sNDA for treating adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. The approval is based on accelerated approval criteria, with confirmation…

Read MoreTakeda announces FDA approval for ICLUSIG® in new Ph+ ALL.

Fabric Genomics Teams Up with Intermountain Children’s Health for Precision Diagnosis

Fabric Genomics, a pioneer in AI-driven next-generation sequencing interpretation, has announced a fresh collaboration with Intermountain Children’s Health. This partnership aims to analyze whole genomes of children sequenced by Broad Clinical Labs, facilitating faster diagnosis for children suspected of genetic…

Read MoreFabric Genomics Teams Up with Intermountain Children’s Health for Precision Diagnosis